Skip to main content
PACIFIC EDGE LIMITED logo

PACIFIC EDGE LIMITED — Investor Relations & Filings

Ticker · PEB ISIN · NZPEBE0002S1 LEI · 9845007EDCF068FFEA12 ASX Professional, scientific and technical activities
Open in API
Filings indexed 747 across all filing types
Latest filing 2022-07-27 Board/Management Inform…
Country NZ New Zealand
Listing ASX PEB

About PACIFIC EDGE LIMITED

https://www.pacificedgedx.com/

Pacific Edge Limited is a cancer diagnostics company specializing in the development and commercialization of non-invasive molecular diagnostic tests. The company's primary product suite, Cxbladder, utilizes advanced mRNA biomarker technology to detect and monitor bladder cancer from urine samples. These genomic tests are designed to assist clinicians in the evaluation of patients presenting with hematuria and in the ongoing surveillance of patients previously diagnosed with the disease. By providing high sensitivity and negative predictive value, the Cxbladder suite helps to accurately rule out urothelial carcinoma, potentially reducing the requirement for invasive clinical procedures such as cystoscopy. The company focuses on integrating its diagnostic tools into standard clinical pathways to improve patient outcomes and healthcare efficiency.

Recent filings

Filing Released Lang Actions
Pacific Edge Appoints Chief Operating Officer
Board/Management Information Classification · 100% confidence The document is a company announcement dated 28 July 2022 about the appointment of a new Chief Operating Officer at Pacific Edge. It details the individual's background, role, and expected contributions. There is no financial data, no mention of a report or filing, no regulatory or legal content, and no discussion of financial results or governance changes beyond the appointment. This fits the category of Board/Management Information, which covers announcements of changes in senior management.
2022-07-27 English
Pacific Edge Appoints Chief Operating Officer 2 pages 169.6KB
Board/Management Information Classification · 100% confidence The document is a company announcement dated 28 July 2022 about the appointment of a new Chief Operating Officer at Pacific Edge. It details the individual's background, role, and responsibilities but does not contain any financial data, regulatory filings, or report content. There is no indication of financial results, audit information, or shareholder voting. The content is focused on management changes, specifically the appointment of a senior executive. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 4114 characters, which is consistent with a typical management announcement rather than a full report or regulatory filing.
2022-07-27 English
Pacific Edge 2022 Annual Shareholders Meeting 54 pages 7.5MB
AGM Information Classification · 95% confidence The document is titled as an Annual Shareholders Meeting presentation for Pacific Edge Limited dated 28 July 2022. It contains agenda items typical of an AGM presentation such as Chairman and CEO presentations, shareholder discussion, resolutions, and general business. The content includes forward-looking statements, disclaimers, market and operational highlights, and strategic outlook, which are typical for investor presentations at AGMs. There is no indication that this document is a full Annual Report (10-K), Audit Report, or Earnings Release. The length (15,000 characters) and detailed content support it being a presentation rather than a brief announcement or regulatory filing. Therefore, the document fits best into the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting.
2022-07-27 English
Southern District Health Region Adopts Cxbladder Tests
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 21 July 2022, describing a commercial agreement between Pacific Edge and the Southern District Health Region for the deployment of a diagnostic test. It contains no financial data, no regulatory form references, no voting results, no management or board changes, no earnings or interim report data, and no mention of any report publication or filing. The content is purely an operational business update about a commercial agreement and product deployment. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. Given the nature of the announcement and the absence of financial or regulatory content, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous company announcements that do not fit other specific categories.
2022-07-20 English
Southern District Health Region Adopts Cxbladder Tests 2 pages 220.8KB
Regulatory Filings Classification · 90% confidence The document is a company announcement dated 21 July 2022 from Pacific Edge regarding a commercial agreement with the Southern District Health Region for the use of its Cxbladder tests. It describes the deployment and adoption of a product, clinical utility, and healthcare impact. There are no financial statements, regulatory filings, voting results, or management changes. The document is a business update or commercial announcement rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a general company announcement about a commercial agreement and product adoption, which is best classified under Regulatory Filings (RNS) as a fallback category for miscellaneous announcements that do not fit other specific categories.
2022-07-20 English
Pacific Edge Investor Update: Q1 FY23 Test Volumes Rise 32%
Management Reports Classification · 95% confidence The document is titled 'PACIFIC EDGE LIMITED INVESTOR UPDATE | JULY 2022' and contains detailed information about company operations, including CEO commentary, test volume progress, executive appointments, clinical study progress, and market engagement activities. It includes quantitative data such as quarterly test volumes and clinician counts, and discusses strategic initiatives and clinical studies. The document is approximately 15,000 characters long, indicating it is a substantive report rather than a brief announcement. It is not a transcript of a call, nor a regulatory filing or certification. It is not an annual or interim financial report with full financial statements, but rather an update focused on operational and strategic progress, including management commentary and business trends. This aligns best with a Management Reports (MDA) filing, which covers management's detailed explanation of financial results, business trends, and outlook, including operational metrics and strategic updates. Therefore, the document should be classified as MDA.
2022-07-19 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.